Evidence map›Paper›PMID 31180527›Full record

ArticleMolecular medicine reports2019

High developmental pluripotency‑associated 4 expression promotes cell proliferation and glycolysis, and predicts poor prognosis in non‑small‑cell lung cancer.

Longfei Li, Yufeng Wang, Qiang Wang, Jingming Qu, Xiangju Wei, Jilei Xu, Yuanjin Wang, Feng Suo, Yangjie Zhang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Oncology research · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Longfei LiDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Yufeng WangDepartment of Nuclear Medicine, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Qiang WangDepartment of Radiotherapy and Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Jingming QuDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Xiangju WeiDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Jilei XuDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Yuanjin WangDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Feng SuoDepartment of Cardiothoracic Surgery, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221000, P.R. China.
Yangjie ZhangDepartment of Orthopedics, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650118, P.R. China.
Jiangsu University · CNXuzhou Cancer Hospital · CNKunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The developmental pluripotency‑associated 4 (Dppa4) gene serves critical roles in cell self‑renewal, as well as in cancer development and progression. However, the regulatory role of Dppa4 in non‑small‑cell lung cancer (NSCLC) and its underlying mechanisms remain elusive. The aim of the present study was to investigate the biological function of Dppa4 in NSCLC and its underlying mechanism of action. Dppa4 expression was measured in NSCLC tissue samples and cell lines, and its effect on cell proliferation and the expression of glycolytic enzymes was determined. In addition, the underlying mechanisms of Dppa4‑induced alterations in glycolysis were analyzed. Univariate and multivariate analyses were also performed to analyze the prognostic significance of clinicopathological characteristics. Dppa4 was found to be highly expressed in NSCLC tissues and cell lines. Furthermore, it was observed that Dppa4 was correlated with the degree of tumor differentiation and TNM stage. Univariate and multivariate analyses identified Dppa4 expression and clinical stage as prognostic factors for NSCLC patients. Kaplan‑Meier analysis further revealed that patients with lower Dppa4 expression exhibited a better prognosis. In NSCLC cells, Dppa4 knockdown inhibited cell proliferation, while Dppa4 overexpression enhanced cell proliferation, which was likely mediated by glycolysis promotion. Dppa4 knockdown had no evident effect on the majority of enzymes examined; however, glucose transporter type 4 (GLUT‑4) and pyruvate kinase isozyme M2 were significantly upregulated, and hexokinase II (HK‑II) and lactate dehydrogenase B (LDHB) were downregulated following Dppa4 knockdown. By contrast, Dppa4 overexpression resulted in downregulation of GLUT‑4, and upregulation of HK‑II, enolase and LDHB, whereas it had no effect on other enzymes. Since the most evident effect was observed on LDHB, further functional experiments demonstrated that this enzyme reversed the promoting effects of Dppa4 in NSCLC. In conclusion, Dppa4 promotes NSCLC progression, partly through glycolysis by LDHB. Thus, the Dppa4‑LDHB axis critically contributes to glycolysis in NSCLC cells, thereby promoting NSCLC development and progression.

Indexed as

Gene Expression Regulation, NeoplasticCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationFemaleGlycolysisHumansIsoenzymesL-Lactate DehydrogenaseLung NeoplasmsMaleMiddle AgedNuclear ProteinsPrognosisUp-RegulationDPPA4 protein, humanIsoenzymeslactate dehydrogenase 1L-Lactate DehydrogenaseNuclear Proteins

Identifiers

PMID31180527
PMCPMC6580026
OpenAlexW2945957531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.